(NASDAQ: BCTX) Briacell Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.28%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.17%.
Briacell Therapeutics's earnings in 2025 is -$11,778,491.On average, 1 Wall Street analyst forecast BCTX's earnings for 2025 to be -$9,088,128, with the lowest BCTX earnings forecast at -$9,088,128, and the highest BCTX earnings forecast at -$9,088,128. On average, 1 Wall Street analyst forecast BCTX's earnings for 2026 to be -$5,452,877, with the lowest BCTX earnings forecast at -$5,452,877, and the highest BCTX earnings forecast at -$5,452,877.
In 2027, BCTX is forecast to generate -$4,043,290 in earnings, with the lowest earnings forecast at -$4,043,290 and the highest earnings forecast at -$4,043,290.